ArticleCell & bioscience2022
Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's disease.
Article in Cell & bioscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Association between diabetes mellitus and risk of Alzheimer's disease: a meta-analysis and systematic review.Frontiers in endocrinology · 2026Pooled it
- Evaluating the Bidirectional Causal Effects of Alzheimer's Disease Across Multiple Conditions: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies.International journal of molecular sciences · 2025Pooled it
- The landscape of the methodology in drug repurposing using human genomic data: a systematic review.Briefings in bioinformatics · 2024Pooled it
- Dementia risk across distinct metabolic profiles in the UK Biobank.GeroScience · 2026Article
- The immuno-neurological axis: association between autoimmune diseases and dementia risk.GeroScience · 2026Article
- Genomics link obesity and type 2 diabetes to Alzheimer's disease to unveil novel biological insights.medRxiv : the preprint server for health sciences · 2026Article
- TAS2R38 taster variants-linked MGAM expression in Alzheimer's disease: a novel target for precision drug repurposing.Frontiers in aging neuroscience · 2026Article
- TAS2R38-Linked MGAM Expression in Alzheimer's Disease: A Novel Target for Precision Drug Repurposing.medRxiv : the preprint server for health sciences · 2025Article
- Bidirectional Causal Associations Between Endogenous/Exogenous Antioxidant Levels and Risks of Type 1 and Type 2 Diabetes Mellitus and Three Complications.Food science & nutrition · 2025Article
- What Information do Systemic Pathological Changes Bring to the Diagnosis and Treatment of Alzheimer's Disease?Neuroscience bulletin · 2025Review
- Evaluating the Causal Association Between Type 2 Diabetes and Alzheimer's Disease: A Two-Sample Mendelian Randomization Study.Biomedicines · 2025Review
- Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies.Molecular medicine (Cambridge, Mass.) · 2025Review
- Impact of diabetes mellitus on the risk of Alzheimer's disease: a mendelian randomization study.BMC neurology · 2024Article
- Behavioral and Metabolic Effects of ABCG4 KO in the APPJournal of molecular neuroscience : MN · 2024Article
- Identification of potential biomarkers and therapeutic targets related to post-traumatic stress disorder due to traumatic brain injury.European journal of medical research · 2024Article
- Genetic prediction of antihyperglycemic drug targets and risk of epilepsy: a mendelian randomisation study.BMC pharmacology & toxicology · 2024Article
- Investigation of the causal relationship between osteocalcin and dementia: A Mendelian randomization study.Heliyon · 2023Article
- Lower mortality risk in APOE4 carriers with normal cognitive ageing.Scientific reports · 2023Article
- Systems biology approaches to identify potential targets and inhibitors of the intestinal microbiota to treat depression.Scientific reports · 2023Article
- Prevailing Antagonistic Risks in Pleiotropic Associations with Alzheimer's Disease and Diabetes.Journal of Alzheimer's disease : JAD · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite accumulating epidemiological studies support that diabetes increases the risk of Alzheimer's disease (AD), the causal associations between diabetes and AD remain inconclusive. The present study aimed to explore: i) whether diabetes is causally related to the increased risk of AD; ii) and if so, which diabetes-related physiological parameter is associated with AD; iii) why diabetes drugs can be used as candidates for the treatment of AD. Two-sample Mendelian randomization (2SMR) was employed to perform the analysis.
resultsFirstly, the 2SMR analysis provided a suggestive association between genetically predicted type 1 diabetes (T1D) and a slightly increased AD risk (OR = 1.04, 95% CI = [1.01, 1.06]), and type 2 diabetes (T2D) showed a much stronger association with AD risk (OR = 1.34, 95% CI = [1.05, 1.70]). Secondly, further 2SMR analysis revealed that diabetes-related physiological parameters like fasting blood glucose and total cholesterol levels might have a detrimental role in the development of AD. Thirdly, we obtained 74 antidiabetic drugs and identified SNPs to proxy the targets of antidiabetic drugs. 2SMR analysis indicated the expression of three target genes, ETFDH, GANC, and MGAM, were associated with the increased risk of AD, while CPE could be a protective factor for AD. Besides, further PPI network found that GANC interacted with MGAM, and further interacted with CD33, a strong genetic locus related to AD.
conclusionsIn conclusion, the present study provides evidence of a causal association between diabetes and increased risk of AD, and also useful genetic clues for drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.